Astragaloside IV inhibits progression of lung cancer by mediating immune function of Tregs and CTLs by interfering with IDO

Journal of Cancer Research and Clinical Oncology

Volumn 140, Issue 11, 2014, Pages 1883-1890

  Zhang, Anle ^a   Zheng, Yuanhong ^a   Que, Zujun ^a   Zhang, Lingling ^a   Lin, Shengchao ^a   Le, Vanminh ^a   Liu, Jianwen ^a   Tian, Jianhui ^b  

^a EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b LONGHUA HOSPITAL AFFILIATED TO SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

AS IV; Cytotoxic T lymphocytes; IDO; Immunotherapy; Regulatory T cells

Indexed keywords

1 METHYL TRYPTOPHAN; ASTRAGALOSIDE IV; INDOLEAMINE 2,3 DIOXYGENASE; PACLITAXEL; TRYPTOPHAN DERIVATIVE; UNCLASSIFIED DRUG; 1-METHYLTRYPTOPHAN; ANTINEOPLASTIC AGENT; ASTRAGALOSIDE A; IDO1 PROTEIN, MOUSE; SAPONIN; TRITERPENE; TRYPTOPHAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; FLOW CYTOMETRY; IN VITRO STUDY; IN VIVO STUDY; LEWIS LUNG CARCINOMA CELL; LUNG CANCER; MONONUCLEAR CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; UPREGULATION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CANCER TRANSPLANTATION; CARCINOMA, LEWIS LUNG; COCULTURE; DISEASE COURSE; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; IMMUNOLOGY; METABOLISM; PATHOLOGY; TUMOR CELL LINE; TUMOR ESCAPE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, LEWIS LUNG; CELL LINE, TUMOR; COCULTURE TECHNIQUES; DISEASE PROGRESSION; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; PACLITAXEL; SAPONINS; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY; TRITERPENES; TRYPTOPHAN; TUMOR BURDEN; TUMOR ESCAPE;

EID: 84919469543     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-014-1744-x     Document Type: Article

References (29)

1. Boon T, van der Bruggen P (1996) Human tumor antigens recognized by T lymphocytes. J Exp Med 183:725–729
2. Chatila TA (2005) Role of regulatory T cells in human diseases. J Allergy Clin Immunol 116:949–959 quiz 60
3. Chen YH, Kuo ML, Cheng PJ, Hsaio HS, Lee PT, Lin SJ (2012) Regulation of CD28 expression on umbilical cord blood and adult peripheral blood CD8+ T cells by interleukin(IL)-15/IL-21. Cytokine 58(1):40–46
4. Du X, Zhao B, Li J, Cao X, Diao M, Feng H, Chen X, Chen Z, Zeng X (2012) Astragalus polysaccharides enhance immune responses of HBV DNA vaccination via promoting the dendritic cell maturation and suppressing Treg frequency in mice. Int Immunopharmacol 14(4):463–470
5. Ercolini AM et al (2005) Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med 201:1591–1602
6. Fallarino F, Grohmann U, Vacca C, Bianchi R, Orabona C, Spreca A et al (2002) T cell apoptosis by tryptophan catabolism. Cell Death Diff 9:1069–1077
7. Fallarino F, Grohmann U, You S, McGrath BC, Cavener DR, Vacca C et al (2006) The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol 176:6752–6761
8. Friberg M, Jennings R, Alsarraj M, Dessureault S, Cantor A, Extermann M et al (2002) Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int J Cancer 101:151–155
9. Godin-Ethier J, Hanafi LA, Duvignaud JB, Leclerc D, Lapointe R (2011) IDO expression by human B lymphocytes in response to T lymphocyte stimuli and TLR engagement is biologically inactive. Mol Immunol 49(1–2):253–259
10. Huang LF, Yao YM, Li JF, Zhang SW, Li WX, Dong N, Yu Y, Sheng ZY (2012) The effect of Astragaloside IV on immune function of regulatory T cell mediated by high mobility group box 1 protein in vitro. Fitoterapia 83(8):1514–1522
11. Hwang SL, Chung NP, Chan JK, Lin CL (2005) Indoleamine 2,3-dioxygenase (IDO) is essential for dendritic cell activation and chemotactic responsiveness to chemokines. Cell Res 15(3):167–175
12. Li X, Wang X, Han C, Wang X, Xing G, Zhou L, Li G, Niu Y (2013a) Astragaloside IV suppresses collagen production of activated HSCs via oxidative stress-mediated p38 MAPK pathway. Free Radic Biol Med 60:168–176
13. Li X, Wang X, Han C, Wang X, Xing G, Zhou L, Li G, Niu Y (2013b) Astragaloside IV suppresses collagen production of activated HSCs via oxidative stress-mediated p38 MAPK pathway. Free Radic Biol Med 60:168–176
14. Muller AJ, Scherle PA (2006) Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. Nat Rev Cancer 6:613–625
15. Munn DH (2006) Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation. Curr Opin Immunol 18(2):220–225
16. Munn DH, Mellor AL (2007) Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 117:1147–1154
17. Nguyen H, Weng NP (2010) IL-21 preferentially enhances IL-15-mediated homeostatic proliferation of human CD28+ CD8 memory T cells throughout the adult age span. J Leukoc Biol 87(1):43–49
18. Nishikawa H et al (2005) Accelerated chemically induced tumor development mediated by CD4+CD25+ regulatory T cells in wild-type hosts. Proc Natl Acad Sci USA 102:9253–9257
19. Prendergast GC (2008) Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene 27(28):3889–3900
20. Stone TW, Darlington LG (2002) Endogenous kynurenines as targets for drug discovery and development. Nat Rev Drug Discov 1:609–620
21. Sun J, Yu J, Li H, Yang L, Wei F, Yu W, Liu J, Ren X (2011) Upregulated expression of indoleamine 2,3-dioxygenase in CHO cells induces apoptosis of competent T cells and increases proportion of Treg cells. J Exp Clin Cancer Res 30:82
22. Sutmuller RP et al (2001) Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 194:823–832
23. Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N et al (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9:1269–1274
24. Wu X, Peng M, Huang B, Zhang H, Wang H, Huang B, Xue Z, Zhang L, Da Y, Yang D, Yao Z, Zhang R (2013) Immune microenvironment profiles of tumor immune equilibrium and immune escape states of mouse sarcoma. Cancer Lett 340(1):124–133
25. Yang Y, Huang CT, Huang X, Pardoll DM (2004) Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat Immunol 5:508–515
26. Yigit R, Massuger LF, Figdor CG, Torensma R (2010) Ovarian cancer creates a suppressive microenvironment to escape immune elimination. Gynecol Oncol 117(2):366–372
27. Yoshida N, Ino K, Ishida Y, Kajiyama H, Yamamoto E, Shibata K, Terauchi M, Nawa A, Akimoto H, Takikawa O, Isobe K, Kikkawa F (2008) Overexpression of indoleamine 2,3-dioxygenase in human endometrial carcinoma cells induces rapid tumor growth in a mouse xenograft model. Clin Cancer Res 14(22):7251–7259
28. Yu P et al (2005) Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med 201:779–791
29. Zheng X, Koropatnick J, Li M, Zhang X, Ling F, Ren X, Hao X, Sun H, Vladau C, Franek JA, Feng B, Urquhart BL, Zhong R, Freeman DJ, Garcia B, Min WP (2006) Reinstalling antitumor immunity by inhibiting tumor-derived immunosuppressive molecule IDO through RNA interference. J Immunol 177(8):5639–5646